Ideaya Biosciences (United States)
company in South San Francisco, United States
IDYA Nasdaq
SEC CIK 1676725
Follow Ideaya Biosciences (United States)
Weekly email: filings, results
Revenue, last quarter
$10.2M
−95.1% vs same quarter last year
Net income
−$125.7M
−205.5% vs same quarter last year
EPS, diluted
−$1.22
−191.7% vs same quarter last year
Operating cash flow
−$93.5M
−165.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $218.7M | −$113.7M |
| FY24 | $7M | −$274.5M |
| FY23 | $23.4M | −$113M |
| FY22 | $50.9M | −$58.7M |
| FY21 | $27.9M | −$49.8M |
| FY20 | $19.5M | −$34.5M |
| FY19 | $0 | −$42M |
| FY18 | - | −$34.3M |
| FY17 | - | −$11.9M |
| FY16 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −72.8% | −52% |
| FY24 | −4671.1% | −3921.1% |
| FY23 | −574.9% | −483% |
| FY22 | −122.7% | −115.2% |
| FY21 | −179.9% | −178.1% |
| FY20 | −180.9% | −176.6% |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
| FY16 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$73.5M |
| FY24 | −$251.4M |
| FY23 | −$117.6M |
| FY22 | −$90.6M |
| FY21 | −$58.4M |
| FY20 | $55M |
| FY19 | −$40.7M |
| FY18 | −$29.3M |
| FY17 | −$14M |
| FY16 | - |
- Ideaya Biosciences (United States)
- Healthcare median
Show the numbers
| Year | Ideaya Biosciences (United States) | Healthcare median |
|---|---|---|
| FY25 | −52% | −30.6% |
| FY24 | −3921.1% | −47% |
| FY23 | −483% | −58% |
| FY22 | −115.2% | −80.4% |
| FY21 | −178.1% | −71.8% |
| FY20 | −176.6% | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |